



ANDA 216064

ANDA TENTATIVE APPROVAL

Lupin Pharmaceuticals, Inc.
U.S. Agent for Lupin Limited
111 South Calvert Street
Harborplace Tower, 21st Floor
Baltimore, MD 21202
Attention: Debashis Mohanty
Associate Director, Regulatory Affairs

Dear Debashis Mohanty:

This letter is in reference to your abbreviated new drug application (ANDA) received for review on April 12, 2021, submitted pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for Valbenazine Capsules, 40 mg, 60 mg, and 80 mg.

Reference is also made to the complete response letter issued by this office on November 23, 2022, and to any amendments thereafter.

We have completed the review of this ANDA and have concluded that adequate information has been presented to demonstrate that the drug meets the requirements for approval under the FD&C Act. We have determined your Valbenazine Capsules, 40 mg, 60 mg, and 80 mg to be bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Ingrezza Capsules, 40 mg, 60 mg, and 80 mg, of Neurocrine Biosciences, Inc. (Neurocrine).

However, we are unable to grant final approval to your ANDA at this time because of the patent issue noted below. Therefore, the ANDA is **tentatively approved**. This determination is based upon information available to the Agency at this time (e.g., information in your ANDA and the status of current good manufacturing practices (cGMPs) of the facilities used in the manufacturing and testing of the drug product). This determination is subject to change on the basis of new information that may come to our attention. This letter does not address issues related to the 180-day exclusivity provisions under section 505(j)(5)(B)(iv) of the FD&C Act.

The reference listed drug (RLD) upon which you have based your ANDA, Neurocrine's Ingrezza Capsules, 40 mg, 60 mg, and 80 mg, is subject to periods of patent protection. The following patents and expiration dates are currently listed in the Agency's publication titled *Approved Drug Products with Therapeutic Equivalence Evaluations* (the "Orange Book"):

<u>U.S. Patent Number</u>	<u>Expiration Date</u>
8,039,627 (the '627 patent)	April 11, 2031
8,357,697 (the '697 patent)	November 8, 2027
10,065,952 (the '952 patent)	October 28, 2036
10,844,058 (the '058 patent)	October 28, 2036
10,851,103 (the '103 patent)	October 28, 2036
10,851,104 (the '104 patent)	October 28, 2036
10,857,137 (the '137 patent)	October 10, 2037
10,857,148 (the '148 patent)	October 10, 2037
10,874,648 (the '648 patent)	October 10, 2037
10,906,902 (the '902 patent)	December 22, 2036
10,906,903 (the '903 patent)	December 22, 2036
10,912,771 (the '771 patent)	October 10, 2037
10,919,892 (the '892 patent)	December 22, 2036
10,940,141 (the '141 patent)	August 10, 2040
10,952,997 (the '997 patent)	October 10, 2037
10,993,941 (the '941 patent)	October 10, 2037
11,026,931 (the '931 patent)	August 14, 2039
11,026,939 (the '939 patent)	September 18, 2038
11,040,029 (the '029 patent)	October 10, 2037
11,311,532 (the '532 patent)	September 18, 2038

Your ANDA contains paragraph IV certifications to each of the patents¹ under section 505(j)(2)(A)(vii)(IV) of the FD&C Act stating that the patents are invalid, unenforceable, or will not be infringed by your manufacture, use, or sale of Valbenazine Capsules,

40 mg, 60 mg, and 80 mg, under this ANDA. You have notified the Agency that Lupin Limited (Lupin) complied with the requirements of section 505(j)(2)(B) of the FD&C Act. With respect to the 40 mg and 80 mg strengths, litigation was initiated within the statutory 45-day period against Lupin for infringement of the '627, '697, '952, '058, '103, '104, '137, '148, '648, '902, '903, '771, '892, '141 and '997 patents in the United States District Court for the District of Delaware [Neurocrine Biosciences, Inc., v. Lupin Limited, Lupin Pharmaceuticals, Inc., Lupin Inc., and Lupin Atlantis Holdings S.A., Civil Action No. 21-01042]. With respect to the 60 mg strength, litigation was initiated within the statutory 45-day period against Lupin for infringement of the '627, '697, '952, '058, '103, '104, '137, '148, '648, '902, '903, '771, '892, '141, '997, '941, '931, '939, and '029 patents in the United States District Court for the District of Delaware [Neurocrine Biosciences, Inc., v. Lupin Limited, Lupin Pharmaceuticals, Inc., Lupin Inc., and Lupin Atlantis Holdings S.A., Civil Action No. 22-00639].

Therefore, final approval for the 40 mg and 80 mg strengths cannot be granted until:

1. a. the expiration of the 7.5-year period provided for in sections 505(j)(5)(B)(iii) and 505(j)(5)(F)(ii) of the FD&C Act,
 - b. The date the court decides² that the '627, '697, '952, '058, '103, '104, '137, '148, '648, '902, '903, '771, '892, '141, and '997 patents are invalid or not infringed (see sections 505(j)(5)(B)(iii)(I), (II), and (III) of the FD&C Act), or
 - c. the '627, '697, '952, '058, '103, '104, '137, '148, '648, '902, '903, '771, '892, '141, and '997 patents have expired, and
2. The Agency is assured there is no new information that would affect whether final approval should be granted.

And final approval for the 60 mg strength cannot be granted until:

1. a. the expiration of the 30-month period provided for in section 505(j)(5)(B)(iii) of the FD&C Act,
 - b. The date the court decides² that the '627, '697, '952, '058, '103, '104, '137, '148, '648, '902, '903, '771, '892, '141, '997, '941, '931, '939, and '029 patents are invalid or not infringed (see sections 505(j)(5)(B)(iii)(I), (II), and (III) of the FD&C Act), or
 - c. the '627, '697, '952, '058, '103, '104, '137, '148, '648, '902, '903, '771, '892, '141, '997, '941, '931, '939, and '029 patents have expired, and
2. The Agency is assured there is no new information that would affect whether final approval should be granted.

Please note that if FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for a listed drug, an ANDA citing that listed drug also will be required to have a REMS. See section 505-1(i) of the FD&C Act.

RESUBMISSION

To request final approval, please submit an amendment titled "FINAL APPROVAL REQUESTED" with enough time to permit FDA review prior to the date you believe that your ANDA will be eligible for final approval. A request for final approval that contains no new data, information, or other changes to the ANDA generally requires a period of 3 months for Agency review. Accordingly, such a request for final approval should be submitted no later than 3 months prior to the date on which you seek approval. A request for final approval that contains substantive changes to this ANDA or changes in the status of the manufacturing and testing facilities' compliance with cGMPs will be classified and reviewed according to OGD policy in effect at the time of receipt. Applicants should review available agency guidance for industry related to amendments under the generic drug user fee program to determine the duration of Agency review needed to review the changes submitted. As part of this consideration, applicants should monitor any changes to the RLD that occur after tentative approval, including changes in labeling, patent or exclusivity information, or marketing status. The submission of multiple amendments prior to final approval may also result in a delay in the issuance of the final approval letter.

The amendment requesting final approval should provide the legal/regulatory basis for your request for final approval and should include a copy of a court decision, settlement or licensing agreement, or other information described in 21 CFR 314.107, as appropriate. It should also identify changes, if any, in the conditions under which the ANDA was tentatively approved, e.g., updated information such as final-printed labeling, chemistry, manufacturing, and controls data as appropriate. This amendment should be submitted even if none of these changes were made, and it should be designated clearly in your cover letter as a "FINAL APPROVAL REQUESTED."

In addition to the amendment requested above, the Agency may request, at any time prior to the date of final approval, that you submit an additional amendment containing information as specified by the Agency. Failure to submit either or, if requested, both types of amendments described above may result in a delay in the issuance of the final approval letter.

This drug product may not be marketed without final Agency approval under section 505(j) of the FD&C Act. The introduction or delivery for introduction into interstate commerce of this drug product before the final approval date is prohibited under section 301 of the FD&C Act. Also, until the Agency issues the final approval letter, this drug product will not be deemed approved for marketing under section 505(j) of the FD&C Act, and will not be listed in the Orange Book.

ANNUAL FACILITY FEES

The Generic Drug User Fee Amendments of 2012 (GDUFA) (Public Law 112-144, Title III) established certain provisions³ with respect to self-identification of facilities and payment of annual facility fees. ANDAs that identify at least one facility that is referenced in an approved ANDA are subject to the self-identification requirement and payment of an annual facility fee. Self-identification must occur by June 1st of each year for the next fiscal year. Facility fees must be paid each year by the date specified in the *Federal Register* notice announcing facility fee amounts.

All finished dosage forms or active pharmaceutical ingredients manufactured in a facility that has not met its obligations to self-identify or to pay fees when they are due will be deemed misbranded. This means that it will be a violation of federal law to ship these products in interstate commerce or to import them into the United States. Such violations can result in prosecution of those responsible, injunctions, or seizures of misbranded products. Products misbranded because of failure to self-identify or pay facility fees are subject to being denied entry into the United States.

In addition, we note that GDUFA requires that certain non-manufacturing sites and organizations listed in generic drug submissions comply with the self-identification requirement. The failure of any facility, site, or organization to comply with its obligation to self-identify and/or to pay fees when due may raise significant concerns about that site or organization and is a factor that may increase the likelihood of a site inspection prior to approval. FDA does not expect to give priority to completion of inspections that are required simply because facilities, sites, or organizations fail to comply with the law requiring self-identification or fee payment.

For further information on the status of this ANDA or upon submitting an amendment to the ANDA, please contact Catherine Morales, Regulatory Project Manager, at (301) 796 - 3585.

Sincerely yours,

{See appended electronic signature page}

For Edward M. Sherwood
Director
Office of Regulatory Operations
Office of Generic Drugs
Center for Drug Evaluation and Research

-
- ¹ With respect to the 40 mg and 80 mg strengths, the Agency notes that the '941, '931, '939, '029 and '532 patents were submitted to the Agency after submission of your ANDA. Litigation, if any, with respect to these patents would not create a statutory stay of approval. With respect to the 60 mg strength, the Agency notes that the '532 patent was submitted to the Agency after submission of your ANDA. Litigation, if any, with respect to this patent would not create a statutory stay of approval.
 - ² This decision may be either a decision of the district court or the court of appeals, whichever court is the first to decide that the patent is invalid or not infringed.
 - ³ Some of these provisions were amended by the Generic Drug User Fee Amendments of 2017 (GDUFA II) (Public Law 115-52, Title III)



John
Ibrahim

Digitally signed by John Ibrahim
Date: 3/24/2023 10:27:25AM
GUID: 542af06d0124375c12e8c1d9fc86e87c